Form 4: Syros Pharmaceuticals Director Richard A. Young Reports Stock Transactions

Director Richard A. Young of Syros Pharmaceuticals reports the vesting of restricted stock units and subsequent disposal of shares.

Summary

• On September 16, 2024, Richard A. Young, a director of Syros Pharmaceuticals, had 2,667 restricted stock units (RSUs) vest.
• Upon vesting, these RSUs converted into 2,667 shares of common stock.
• Simultaneously, Mr. Young disposed of 2,667 shares.
• Following these transactions, Mr. Young directly owns 2,667 derivative securities.
• The RSUs were granted on September 16, 2022, and vest in three equal annual installments starting September 16, 2023.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to stock transactions by a company director, and it doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The vesting and subsequent disposal of shares are common occurrences and don't necessarily indicate a change in the director's long-term outlook for the company.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a standard vesting and disposal of shares by a director.

Key Dates

Keywords

Syros Pharmaceuticals, Richard A. Young, Form 4, Stock Transaction, Restricted Stock Units, Director, Vesting